Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
- PMID: 33523336
- DOI: 10.1007/s10557-021-07142-w
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
Abstract
Purpose: It was aimed to determine the aggregated risk of MACE (major adverse cardiovascular events) in stable CAD patients carrying CYP2C19 LoF alleles taking clopidogrel.
Methods: Literature was searched in different databases for relevant studies. Aggregated risk was estimated using a fixed/random effect model where p-value<0.05 was considered statistically significant.
Results: In total, 21 studies with 16,194 stable CAD patients were assessed. It was found that patients treated with clopidogrel carrying either one or two CYP2C19 LoF alleles who underwent PCI were associated with significantly increased risk of MACE compared to non-carriers (OR: 1.71, 95% CI: 1.51-1.94, p<0.00001) that was driven from cardiovascular death (OR: 1.43, 95% CI: 1.02-1.99, p=0.04), myocardial infarction (OR: 1.75, 95% CI: 1.42-2.16, p<0.00001), stroke (OR: 2.30, 95% CI: 1.52-3.47, p<0.0001), and stent thrombosis (OR: 4.08, 95% CI: 2.52-6.61, p<0.00001). It was also found that carriers of two CYP2C19 LoF alleles were associated with a significantly marked risk of MACE than non-carriers (OR: 2.22, 95% CI: 1.60-3.09, p<0.00001). Furthermore, the increased risk of MACE remained markedly significant in Asian patients (OR: 2.03, 95% CI: 1.72-2.40, p<0.00001) and was less significant in western patients (OR: 1.35, 95% CI: 1.11-1.63, p=0.002). Bleeding events were not significantly different in carriers of CYP2C19 LoF alleles compared to non-carriers (OR: 1.11, 95% CI: 0.85-1.45, p=0.43).
Conclusion: Stable CAD patients treated with clopidogrel and carried CYP2C19 LoF alleles undergoing PCI were associated with significantly increased risk of MACE compared to non-carriers, even markedly significant for Asian patients.
Keywords: CYP2C19 LoF alleles; Clopidogrel; Major adverse cardiovascular events; Stable coronary artery disease.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis.Pharmacogenomics. 2022 Feb;23(3):207-220. doi: 10.2217/pgs-2021-0098. Epub 2022 Jan 19. Pharmacogenomics. 2022. PMID: 35042400
-
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.Platelets. 2019;30(2):229-240. doi: 10.1080/09537104.2017.1413178. Epub 2017 Dec 19. Platelets. 2019. PMID: 29257922
-
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443. JAMA. 2020. PMID: 32840598 Free PMC article. Clinical Trial.
-
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Thromb Res. 2015. PMID: 25511576 Review.
-
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.J Clin Pharm Ther. 2022 Aug;47(8):1112-1121. doi: 10.1111/jcpt.13665. Epub 2022 Apr 9. J Clin Pharm Ther. 2022. PMID: 35396752 Review.
Cited by
-
A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel.Sci Rep. 2024 Jan 29;14(1):2358. doi: 10.1038/s41598-024-52540-3. Sci Rep. 2024. PMID: 38286794 Free PMC article.
-
Progress in the clinical effects and adverse reactions of ticagrelor.Thromb J. 2024 Jan 10;22(1):8. doi: 10.1186/s12959-023-00559-3. Thromb J. 2024. PMID: 38200557 Free PMC article. Review.
-
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.Front Cardiovasc Med. 2023 Feb 8;9:1027892. doi: 10.3389/fcvm.2022.1027892. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36843628 Free PMC article.
-
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.Eur J Med Res. 2023 Feb 24;28(1):96. doi: 10.1186/s40001-023-01068-9. Eur J Med Res. 2023. PMID: 36829258 Free PMC article.
-
Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches.Int J Mol Sci. 2022 Mar 18;23(6):3301. doi: 10.3390/ijms23063301. Int J Mol Sci. 2022. PMID: 35328719 Free PMC article. Review.
References
-
- Braun MM, Stevens WABC. Stable coronary artery disease:treatment. Am Fam Physician. 2018;97:376–84. - PubMed
-
- Niu X, Mao L, Huang Y, Baral S, Li JY, Gao Y, et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: a systematic review and meta-analysis. J Huazhong Univ Sci Technol - Med Sci. 2015;35:147–56.
-
- Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891–6. - PubMed
-
- Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013;6:1166–75. - PubMed
-
- Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474–83. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
